| Today's Top Story |  |  | | - Amgen plans launch of blockbusters' biosimilars in 4 years
Amgen intends to commercialize biosimilar versions of six of the biggest-selling biologic drugs including Humira and Remicade, the main rivals of its own rheumatoid arthritis treatment Enbrel, starting in 2017, CEO Robert Bradway said. The biotech firm sees biosimilars as a multi-billion dollar opportunity, and it expects to become a major player in the market once the approval pathway is finalized. Reuters (2/7)       | Health Care & Policy | | | | - Sequester could slow or stop FDA reviews, analyst warns
FDA operations will be limited by budget sequestration if lawmakers don't move to stop an 8.2% automatic cut before March 1, the consulting firm Avalere Health warned. "An underfunded FDA could lead to FDA review clocks being reset or delayed, which would affect a sponsor's ability to obtain product approval -- thus delaying patient access to cutting edge medical innovations," Avalere said in its report. The Hill/Healthwatch blog (2/5) - Stem cells survive being "printed" in 3D pattern
Researchers from the University of Edinburgh in Scotland developed a three-dimensional printer that can gently place living stem cells in uniform droplets, a step toward the possible construction of tissues and organs. More than 95% of the cells were alive a day following printing and more than 89% were alive after three days while maintaining a marker for pluripotency. The findings were reported in the journal Biofabrication. LiveScience.com (2/5) | Company & Financial News | | | | - Ironwood goes old-school with focus on long term
Instead of focusing on a rare disease and trying to make itself an attractive buyout target as many other biopharmaceutical companies are doing, Ironwood Pharmaceuticals is staffing up and marketing a drug with blockbuster potential. Ironwood and its partner, Forest Laboratories, have skipped television ads in favor of an Internet search engine optimization strategy and are talking with payers to ensure reimbursement and low patient copays. Xconomy/Boston (2/6) | Food & Agriculture | | | | | Industrial & Environmental | | | | - Report: Innovations are needed to boost biomass availability
Improvements in feedstock development and production are needed to keep up with the growing demand for biomass supplies, according to a report by Lux Research. "[M]eeting the growing challenge will require feedstock innovations such as crop modification, new value chain configurations, and agronomic technology improvements like irrigation and biosensors," said Lux Research analyst Kalib Kersh in a statement. The Boston Globe (tiered subscription model) (2/5)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| SmartQuote | | | |  | If you want to make enemies, try to change something."
--Woodrow Wilson,
28th U.S. president  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, February 07, 2013
- Wednesday, February 06, 2013
- Tuesday, February 05, 2013
- Monday, February 04, 2013
- Friday, February 01, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment